Drug Profile
Neoepitope immunotherapy - IMV
Alternative Names: DPX-NEOLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Immunovaccine
- Developer IMV; University of Connecticut
- Class Cancer vaccines; Immunotherapies; Proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ovarian cancer